SUMMARY Thirty-seven patients with chronic back pain were entered into a randomised, 3-way, double-blind, cross-over comparison of naproxen sodium 550 mg twice daily, diflunisal 500 mg twice daily, and placebo. Each treatment was given for 14 days after a preadmission wash-out week during which only paracetamol was allowed. Patients were assessed on admission and at the end of each treatment with respect to global pain, night pain, pain on movement, and pain on standing. Both visual analogue scales and simple descriptive scales were used to measure pain. Side effects were elicited by a nonleading question. Both methods of pain measurement gave similar results and were highly correlated. Naproxen sodium was superior to placebo in relieving global pain and, depending on the method of measurement, in relieving night pain and pain on movement. Diflunisal showed no significant differences from placebo. Side effects were similar on all 3 treatments. The final preference of the patients was significantly in favour of the active treatments.
Both naproxen sodium and diflunisal are analgesics with anti-inflammatory properties that are used primarily for their analgesic effect. Diflunisal has been heralded as the safer aspirin. In a controlled general-practitioner study1 it was reported that diflunisal had 3 advantages over aspirin in being more effective, more convenient (twice daily dosage), and less likely to cause gastric side effects in patients treated for acute pain. However, there has been some evidence23 to suggest that even this 'safe' drug may cause acute peptic ulcer. Naproxen sodium has been shown to produce significantly higher and earlier plasma levels of naproxen than an equivalent dose of the free acid, naproxen.4 It is therefore suited for use in acute conditions. Naproxen sodium has shown to be as effective as indomethacin in treating acute musculoskeletal disorders in general practice.5
The Statistical methods. Efficacy data from the SDS and VAS scales were analysed by a nonorthogonal analysis of variance.
Results
Thirty-seven patients, 24 women and 13 men, were entered into the study. Disease duration ranged from less than 1 year to 22 years, with a median of 3 years (see Table 1 ).
Changes in the efficacy measurements on treatments are shown in Fig. 1 Table 3 . The range of side effects was similar during all 3 treatment periods.
Reasons for discontinuation of drugs are summar- 
